Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.42 |
| ▸ | PDE9A | O76083 | 15/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051051 | 0.84 | KDM4E (0.42) | KDM4EKMT2APDE1CPDE9A | |
| SCHEMBL23918240 | 0.84 | KDM4E (0.42) | KDM4EKMT2APDE1CPDE9A | |
| SCHEMBL29175001 | 0.84 | KDM4E (0.42) | KDM4EKMT2APDE1CPDE9APDE2A | |
| SCHEMBL30095729 | 0.84 | KDM4E (0.42) | KDM4EKMT2APDE1CPDE9APDE2A | |
| SCHEMBL31403549 | 0.83 | KDM4E (0.41) | KDM4EKMT2APDE1CPDE9A | |
| SCHEMBL31403622 | 0.83 | ADORA2A (0.46) | KDM4EKMT2APDE1CPDE9A | |
| SCHEMBL29174857 | 0.83 | KDM4E (0.44) | KDM4EKMT2APDE1CPDE9APDE2A | |
| SCHEMBL24500179 | 0.83 | KDM4E (0.41) | KDM4EKMT2APDE1CPDE9APDE2A | |
| SCHEMBL30095905 | 0.83 | KDM4E (0.44) | KDM4EKMT2APDE1CPDE9APDE2A | |
| SCHEMBL30095889 | 0.83 | KDM4E (0.44) | KDM4EKMT2APDE1CPDE9APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-15 | — | — | US | disclosed |
| EP-3892622-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-24 | — | — | EP | disclosed |
| EP-3892623-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-10 | — | — | EP | disclosed |
| EP-4346806-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117529315-A | Imidazole-containing ALK2 kinase inhibitors | 生物水晶制药公司 | 2024-02-06 | — | — | CN | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014144455-A1 | 1 -PHENOXY-3-(ALKYLAMINO)-PROPAN-2-OL DERIVATIVES AS CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144455-A1 | 1 -PHENOXY-3-(ALKYLAMINO)-PROPAN-2-OL DERIVATIVES AS CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138485-A1 | EX VIVO PRODUCTION OF PLATELETS FROM HEMATOPOIETIC STEM CELLS AND THE PRODUCT THEREOF | IRM LLC (BM) | 2014-09-12 | — | — | WO | disclosed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | KDM4E 930/4885KMT2A 1360/4885PDE1C 28/4885 |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | KDM4E 930/4885KMT2A 1360/4885PDE1C 28/4885 |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | KDM4E 550/4885KMT2A 1980/4885PDE1C 2327/4885 |
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | KDM4E 507/4885KMT2A 906/4885PDE1C 953/4885 |
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | KDM4E 3494/4885KMT2A 4007/4885PDE1C 2706/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | KDM4E 2200/4885KMT2A 857/4885PDE1C 4872/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | KDM4E 2200/4885KMT2A 857/4885PDE1C 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.